Case Overview: A class action lawsuit alleges that Chattem and Sanofi-Aventis falsely marketed Unisom sleep aid products as "non-habit forming," a claim plaintiffs say is misleading to consumers.

Consumers Affected: People who purchased Unisom sleep aid products marketed as "non-habit forming"

Court: To be confirmed upon case detail availability

Unisom Makers Chattem and Sanofi-Aventis Face Lawsuit Over 'Non-Habit Forming' Sleep Aid Claims

A new class action lawsuit takes aim at the makers of Unisom, one of the country's best-known over-the-counter sleep aids, alleging that its "non-habit forming" marketing claim is false and misleading to consumers who rely on that label when deciding what sleep product to buy.

According to recent class action reporting, the complaint targets Chattem, Inc. and Sanofi-Aventis U.S. LLC — the companies behind the Unisom brand — over what plaintiffs describe as deceptive product labeling that misrepresents the nature of the active ingredients used in the sleep aid.

Lawsuit Claims 'Non-Habit Forming' Label Misrepresents the Product

At the center of the lawsuit is the prominent "non-habit forming" claim displayed on Unisom's packaging. The complaint alleges that this representation is misleading because the product's active ingredients can, in fact, lead to dependence or tolerance with regular use — directly contradicting what the label tells consumers.

The lawsuit alleges that Chattem and Sanofi-Aventis knew, or should have known, that this marketing claim could create a false sense of safety for consumers who may be concerned about the risks associated with sleep medications. According to the complaint, many consumers specifically seek out products labeled "non-habit forming" as a way to avoid dependency — making that claim a material factor in their purchasing decision.

The plaintiff contends that had she known the "non-habit forming" representation was allegedly inaccurate, she would not have purchased the product — or would have paid substantially less for it.

Products at Issue

The lawsuit focuses on Unisom sleep aid products bearing the "non-habit forming" claim on their labeling and marketing materials. Unisom is widely distributed across major U.S. retailers and is among the most recognized sleep aid brands on the market, making its reach — and the potential scope of the consumer class — considerable.

The most commonly used active ingredient in Unisom SleepTabs is doxylamine succinate, an antihistamine. Unisom SleepGels and some other formulations use diphenhydramine HCl. Both are antihistamines approved by the FDA for short-term sleep assistance, though research suggests regular use of antihistamines as sleep aids can lead to reduced effectiveness over time and psychological reliance.

Why the 'Non-Habit Forming' Claim Matters to Consumers

Sleep medication is a category where label transparency carries significant weight. Many consumers actively choose OTC sleep aids over prescription alternatives precisely because of perceived safety profiles — and labels like "non-habit forming" play a direct role in shaping those choices.

The lawsuit alleges that Chattem and Sanofi-Aventis exploited that consumer preference by promoting a characteristic the product does not reliably possess. The complaint frames this as a violation of consumer protection standards, asserting that the companies reaped financial benefit from a claim that allegedly lacks scientific support as applied to their formulations.

According to the filing, the plaintiff suffered economic harm by paying a premium for a product she believed carried a lower risk of dependence than it allegedly does.

Defendant Response

As of the time of this reporting, Chattem and Sanofi-Aventis have not issued a public statement specifically addressing the lawsuit's allegations. Defendants in class action litigation typically deny all material allegations and contest class certification.

A Growing Trend of OTC Label Litigation

This lawsuit fits within a broader pattern of class action litigation targeting over-the-counter health product labeling. Courts across the country have seen a rise in cases challenging wellness and pharmaceutical brands over claims like "natural," "clinically proven," and — increasingly — "non-habit forming." Plaintiffs in these cases typically allege that such labels constitute unfair or deceptive trade practices under state consumer protection statutes.

The Unisom case adds a prominent name to that growing list and may draw increased attention to how sleep aid manufacturers characterize dependency risk on consumer-facing packaging.

Related Cases

• Target's Up & Up Bandages Lawsuit Alleges PFAS Contamination
• NyQuil Maker Faces Class Action Over Product Claims
• Consumer Protection Lawsuits Targeting OTC Health Products

Lawsuit: To be confirmed — Plaintiff v. Chattem, Inc. and Sanofi-Aventis U.S. LLC

Case Number: To be confirmed upon court filing availability

Court: To be confirmed

Plaintiffs' Attorney(s): To be confirmed

Have you purchased Unisom or another sleep aid based on a "non-habit forming" label claim? Share your experience in the comments below.